Drug development for Alzheimer's disease and dementia is a rapidly evolving field focused on combating cognitive decline and managing symptoms. Researchers target beta-amyloid plaques and tau tangles, pivotal in Alzheimer's pathology, alongside efforts to enhance neurotransmitter function and mitigate brain inflammation. Innovative therapies include monoclonal antibodies to clear amyloid plaques, small molecules targeting tau protein aggregation, and drugs modulating neurotransmitters like acetylcholine. Regenerative strategies such as stem cell therapies aim to repair brain tissue damage. This multifaceted approach aims not only to alleviate symptoms but also to slow or halt disease progression, offering promise for enhancing patients' quality of life in the future.
Title : Make a difference
Jacqueline Tuppen, Dementia UK, United Kingdom
Title : Imaging brain clearance in Alzheimer’s disease
Jun Hua, Johns Hopkins University , United States
Title : Association between APOE allele prevalence and Alzheimer's disease risk in Southwestern Uganda
Frank Balikoowa, African Research Center for Ageing & Dementia, Uganda
Title : Healthcare professionals in Somaliland had low levels of knowledge and attitudes towards dementia care: A pilot survey
Mohamed Abdilahi Duale, Frantz Fanon University, Somalia
Title : Association between depressive symptoms and cognitive impairment severity in a real-world memory clinic cohort
Yun Ju Hsieh, Taipei City Hospital, Taiwan
Title : Neuromodulation of scalp electroacupuncture in the treatment of autism spectrum disorder
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China